Heat Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Heat Biologics's estimated annual revenue is currently $7.5M per year.
- Heat Biologics's estimated revenue per employee is $258,621
- Heat Biologics's total funding is $50.1M.
Employee Data
- Heat Biologics has 29 Employees.
- Heat Biologics grew their employee count by -15% last year.
Heat Biologics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Chemistry and Manufacturing Controls | Reveal Email/Phone |
2 | VP Research | Reveal Email/Phone |
3 | SVP Product Development and Portfolio Strategy | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Accounts Payable Manager | Reveal Email/Phone |
6 | Senior Business Development Advisor | Reveal Email/Phone |
Heat Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Heat Biologics?
Heat Biologics (Heat) is a clinical-stage company focused on the development and commercialization of its HS-System, a platform technology that offers a novel approach to treating cancer and other diseases by using live, modified cell lines to activate the immune system against specific defined targets. Heat is currently Phase I/II clinical trial with its first drug for patients with advanced non-small cell lung cancer.
keywords:N/A$50.1M
Total Funding
29
Number of Employees
$7.5M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Heat Biologics News
The company falls under the umbrella of Heat Biologics, a clinical-stage biopharmaceutical company focused on biodefense assets. The project is...
Morrisville biopharmaceutical firm Heat Biologics (NYSE: HTBX) has had a busy week. The company on Monday unveiled plans for one of its...
Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics ... DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat...
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021 Download as PDFApril 12, 2021 DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 29 | 0% | N/A |
#2 | $4.3M | 29 | -9% | N/A |
#3 | N/A | 29 | 32% | N/A |
#4 | $5.8M | 29 | -43% | N/A |
#5 | $2M | 29 | 16% | N/A |